Combinations of modalities for the treatment of diabetes
A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.
1. A method of treating diabetes mellitus in a subject comprising administering to the subject:
a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) fusion protein in a pharmaceutically acceptable carrier, and
preproinsulin in a pharmaceutically acceptable carrier.
2. The method of claim 1 , wherein said CTLA4 fusion protein is abatacept.
3. The method of claim 1 , wherein said preproinsulin comprises amino acids 33-47 of SEQ ID NO:1.
4. The method of claim 1 , wherein said pharmaceutically acceptable carrier is an oil-based carrier.
5. The method of claim 4 , wherein said oil-based carrier is IFA or Montanide ISA.